Complete Genomics, a struggling DNA sequencing company in Silicon Valley, said on Monday that it had agreed to be acquired for USD 117.6 million by BGI-Shenzhen, a Chinese company that operates the world’s largest sequencing operation. The deal will need antitrust clearance, because of two key players in the DNA sequencing business in a highly capital intensive and research intensive industry, as well as clearance from a national security review by the Committee on Foreign Investment in the United States. It also requires approval from certain governmental authorities in China.
Featured News
FTC Moves to Block Henkel Deal for Liquid Nails Owner
Dec 14, 2025 by
CPI
US Appeals Court Hears Challenge to False Claims Act Whistleblower Powers
Dec 14, 2025 by
CPI
Federal Judge Again Throws Out Antitrust Lawsuit Against Visa
Dec 14, 2025 by
CPI
California Judge Expands Antitrust Lawsuit Against Live Nation and Ticketmaster
Dec 14, 2025 by
CPI
NY Laws Requires Disclosure of AI Actors in Ads, Limit Use of Person’s Image After Death
Dec 12, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Acqui-hiring
Dec 11, 2025 by
CPI
Anticompetitive Effects of Acquihires: Labor and Product Markets
Dec 11, 2025 by
Heski Bar-Isaac, Justin Johnson & Volker Nocke
Acquihires In the Technology Sector: Antitrust Scrutiny Through the Lens of Economics
Dec 11, 2025 by
Juliette Caminade, Rebecca Kirk Fair, Zsolt Udvari & Jeanne Vellard Smith
M&A in the AI Era: Considerations for Acquihiring
Dec 11, 2025 by
Ingrid Vandenborre, Kenneth Schwartz, Christopher Barlow, Page Griffin, Michael Cardella, Stuart Levi, Taylor Votek, Benjamin Salzer, Lisa G. Liu & Liz Kraus
Lock Them Up, or Take No Prisoners? Merger Policy and Acquiring AI Talent: Human Rights and Other Inconvenient Facts
Dec 11, 2025 by
Simon R. Pritchard